Abstract: The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and/or are exposed to the cells prior to administration.
Type:
Grant
Filed:
February 10, 2022
Date of Patent:
April 25, 2023
Assignee:
Baylor College of Medicine
Inventors:
Bert W. O'Malley, Sang Jun Han, David M. Lonard, Bryan Nikolai, Prashi Jain, Yosef Gilad, Clifford Dacso
Abstract: The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and/or are exposed to the cells prior to administration.
Type:
Grant
Filed:
February 10, 2022
Date of Patent:
April 25, 2023
Assignee:
Baylor College of Medicine
Inventors:
Bert W. O'Malley, Sang Jun Han, David M. Lonard, Bryan Nikolai, Prashi Jain, Yosef Gilad, Clifford Dacso
Abstract: The present invention relates to the field of immunology, molecular biology and therapeutics. In particular, the invention relates to novel artificial feeder cells for activation and expansion of natural killer (NK) cells. The artificial feeder cell expresses endogenous ligands (HLA C1, C2, 5 and Bw4 type) for killer cell immunoglobulin-like receptors (KIRs), non-KIR binding Bw6 ligand, endogenous HLA-E-ligand for inhibitory NKG2A receptor, and comprises at least one stimulatory cytokine either membrane bound or secreted or at least one co-stimulatory ligand where those ligands and cytokines each specifically bind to a cognate receptor on a NK cell of interest, thereby mediating expansion of the NK cell. The invention can be used as an “off the 10 shelf” artificial feeder cell that can be readily designed to expand a NK cell or a NK subset of interest and also specifically expand NK cells modified with a chimeric antigen receptor (CAR).
Abstract: Phycoerythrin (PE) and peptide:MHCII (p:MHCII) reactive monoclonal antibodies; methods to generate monoclonal antibodies including, for example, peptide:MHC (p:MHC) reactive monoclonal antibodies; compositions including monoclonal antibodies; and uses thereof.
Type:
Grant
Filed:
April 13, 2018
Date of Patent:
January 24, 2023
Assignee:
REGENTS OF THE UNIVERSITY OF MINNESOTA
Inventors:
Brian T. Fife, Justin A. Spanier, Marc K. Jenkins, Justin J. Taylor
Abstract: Disclosed are: a method for activating a helper T cell, which comprises the step of adding a WT1 peptide to an antigen-presenting cell to activate the helper T cell, wherein the WT1 peptide is capable of binding to any one selected from an HLA-DRB1*1501 molecule, an HLA-DPB1*0901 molecule and an HLA-DPB1*0501 molecule; a composition for use in the method; a therapeutic and/or prophylactic method for cancer by activating a helper T cell; a pharmaceutical composition for use in the therapeutic and/or prophylactic method; and others.
Type:
Grant
Filed:
October 18, 2018
Date of Patent:
January 17, 2023
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: The present disclosure relates to a chimeric antigen receptor, a nucleic acid, a chimeric antigen receptor expression plasmid, a chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the chimeric antigen receptor expressing cell. The chimeric antigen receptor is specific to human leukocyte antigen G. The nucleic acid encodes the chimeric antigen receptor. The chimeric antigen receptor expression plasmid expresses the chimeric antigen receptor. The chimeric antigen receptor expressing cell is obtained by transducing the chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.
Abstract: An object of the present invention is to discover a novel peptide useful as an active ingredient in an agent for treating or preventing cancer, and to provide the use of the polypeptide as an immune inducer. The immune inducer contains as an active ingredient, the following (i) or (ii): (i) at least one polypeptide having an immune-inducing activity and selected from the group of polypeptides (a) or (b), where: (a) polypeptides consisting of 7 or more consecutive amino acids within the region of positions 24 to 97 in the amino acid sequence represented by SEQ ID NO: 2; and (b) polypeptides comprising one to several amino acid deletions, substitutions and/or additions in the amino acid sequence of any one of the polypeptides (a); and (ii) a recombinant vector comprising at least one polynucleotide encoding any one of the polypeptides, and capable of expressing the polypeptide in vivo.
Abstract: The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and/or are exposed to the cells prior to administration.
Type:
Grant
Filed:
August 27, 2021
Date of Patent:
November 15, 2022
Assignee:
Baylor College of Medicine
Inventors:
Bert W. O'Malley, Sang Jun Han, David M. Lonard, Bryan Nikolai, Prashi Jain, Yosef Gilad, Clifford Dacso
Abstract: The present invention relates generally to immunotherapy. Disclosed herein are methods for obtaining cytolytic differentiated NKG2A?NKG2C+ cells with a given KIR specificity and also compositions comprising these cells as well as the use of these cells for therapy. The NK cell expansion methods provided herein also have non-therapeutic uses.
Abstract: The present invention relates to a vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of the major histocompatibility complex (MHC) class I restricted antigen presentation. The present invention furthermore relates to a method of vaccination of a mammal using the inventive vaccine/inhibitor combination. The present invention also provides kit of parts comprising the inventive vaccine/inhibitor combination, preferably in different parts of the kit, e.g. for prior, concurrent or subsequent administration of the different parts. Additionally the invention relates to a pharmaceutical composition comprising the inventive vaccine/inhibitor combination to further improve the immune response against tumour cells and infected cells having lost the capability of MHC class I restricted antigen presentation.
Type:
Grant
Filed:
July 21, 2017
Date of Patent:
October 4, 2022
Assignee:
CureVac AG
Inventors:
Christina Lorenz, Mariola Fotin-Mleczek, Karl-Josef Kallen
Abstract: The present invention relates to CTL peptide epitopes, high-throughput methods for their identification, and their uses. In particular, the present invention relates to peptide epitopes for cancer immunotherapy and Hepatitis C Virus vaccines. The present invention also relates to methods and systems for identifying antigen-specific CTLs.
Abstract: This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified ?1-?2 domains of NKG2D ligands.
Type:
Grant
Filed:
December 4, 2015
Date of Patent:
September 27, 2022
Assignee:
XYPHOS BIOSCIENCES INC.
Inventors:
Kyle Landgraf, Daniel P. Steiger, Steven R. Williams, David W. Martin
Abstract: Cord blood or peripheral blood NK cells are prepared from whole blood mononuclear cells without the need to isolate CD34+ hematopoietic stem cells or NK cells, and without the need for a feeder layer. Advantageously, the methods presented herein use an enrichment process that uses antiCD16 agonist antibodies, antiCD3 antibodies, and N-803. Moreover, contemplated processes are suitable for adaptation into a fully automated production process (GMP in a box).
Type:
Grant
Filed:
July 8, 2019
Date of Patent:
September 27, 2022
Assignee:
ImmunityBio, Inc.
Inventors:
Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Karl Marquez, Patrick Soon-Shiong
Abstract: The present invention relates to a composition for inducing dendritic cell maturation and a method for maturing dendritic cells. More particularly, the present invention relates to a composition including a fusion protein of Rv2299c and ESAT-6, both derived from M. tuberculosis, as an active ingredient for inducing dendritic cell maturation, and a method for differentiating immature dendritic cells into dendritic cells by using the same. The method of the present invention can increase a dendritic cell immune response in the body.
Type:
Grant
Filed:
November 29, 2018
Date of Patent:
August 16, 2022
Assignee:
Quratis Inc.
Inventors:
Hwa-Jung Kim, Han-Gyu Choi, Sung Jae Shin
Abstract: Multimeric polypeptides and pharmaceutical uses thereof; multimers of alpha3 peptides of an HLA-G antigen and methods of producing such multimers, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection. The multimers include at least two monomers, each of said monomers being selected in the group consisting of a peptide P1 of formula X1-X2, wherein X1 represents a peptidic linker including a cysteine amino acid and X2 represents an alpha3 domain of HLA-G.
Type:
Grant
Filed:
January 11, 2018
Date of Patent:
August 2, 2022
Assignee:
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Inventors:
Joel Le Maoult, Edgardo Delfino Carosella
Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK call cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
Type:
Grant
Filed:
January 22, 2018
Date of Patent:
June 21, 2022
Assignee:
INNATE PHARMA
Inventors:
Alessandro Moretta, Mariella Della Chiesa
Abstract: The present invention relates to a hydroxyapatite and/or tricalcium phosphate powder characterized in that it has undergone at least one sintering step at a temperature between 400° C. and 600° C. The invention also relates to a process for preparing such a powder, and to a composition comprising such a powder for use as an anti-tumour auto-vaccine and particularly in the treatment of the following pathological conditions: osteosarcoma, B or T lymphoma, mammary tumour, melanoma, haemangiosarcoma, mastocytoma, fibrosarcoma, brain tumours and schwannoma in a subject. The present invention also covers a drug combination comprising the composition of the invention and at least one second therapeutic agent, preferably an anti-tumour agent and/or a radiotherapeutic agent.
Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
Type:
Grant
Filed:
February 13, 2018
Date of Patent:
April 12, 2022
Assignee:
BioNTech SE
Inventors:
Ozlem Tureci, Ugur Sahin, Sebastian Kreiter
Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.